Immunovant, Inc. Stock News

Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.

Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.

Immunovant, Inc. (NASDAQ:IMVT ) Q4 2022 Earnings Conference Call June 8, 2022 8:00 AM ET Company Participants Pete Salzmann - CEO Conference Call Participants Robyn Karnauskas - Truist Securities Dere

Immunovant Inc (NASDAQ: IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED).  Im

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today anno

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today annou

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today annou

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today anno

Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022.

Immunovant press release (IMVT): Q3 GAAP EPS of -$0.36 misses by $0.04.Cash balance of $527M (as of Dec

Company Ended the Quarter With Cash of Approximately $527.0 Million Company Ended the Quarter With Cash of Approximately $527.0 Million